Chapter 35: Anticancer Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, um, usually when we talk about medicine, there's this, like, this expectation of precision.

Right.

Yeah, like a targeted strike.

Exactly.

You get a bacterial infection.

You take an antibiotic.

It targets the bacteria and, you know, you go on with your life.

The collateral damage is usually pretty minimal.

We really love to think of therapeutics as these highly specific smart bombs.

I mean, it's a comforting thought for sure.

But then you step into the world of traditional oncology and pharmacology and suddenly that smart bomb looks a lot more like a wrecking ball.

It totally does.

The far -ecological landscape we are exploring today is quite honestly brutal.

It is a biological siege.

So welcome to the show.

We are taking you on a highly focused deep dive into chapter 35 of Lip and Cut Illustrated Reviews, pharmacology seventh edition covering anti -cancer drugs.

And our mission today is to, well, to translate this extraordinarily dense pharmacology chapter into a really clear logical journey for you.

Yeah, because it is dense.

Very.

We are going to connect the cellular physiology directly to the drug targets and then we'll follow those mechanisms straight into the clinical uses and of course the toxicities.

So if you are a college student, you know, seeing this for the first time, the why behind the medicine should make perfect sense by the time we wrap up.

That is the goal.

Yeah.

And the textbook opens up by setting some incredibly high stakes.

It estimates that over 25 % of the United States population will face a cancer diagnosis in their lifetime.

Wow.

Yeah.

More than 1 .6 million new cancer patients are diagnosed every single year.

And the overall five -year survival rate sits at about 68%, which, you know, makes cancer second only to cardiovascular disease as a leading cause of mortality.

And here is the core pharmacological challenge that drives this entire chapter list.

Then a quarter of those patients will be cured solely by local treatments like, you know, surgery or radiation.

Because it spreads.

Exactly.

Because cancer can metastasize, most patients will eventually need systemic chemotherapy to treat the whole body.

But traditional chemotherapy has a notoriously steep ghost response curve.

Meaning you push the dose, you push the toxicity.

Right.

It targets all rapidly dividing cells, normal and abnormal alike.

It doesn't really differentiate well.

Which is exactly why newer agents are trying to shift the paradigm to leverage the immune system or target specific enzymes.

Yeah.

But before we even get to the drugs themselves, we kind of have to look at the battlefield, right?

We need to understand the goals of treatment and the actual physical reality of a tumor.

Clinically, we operate with three main goals.

The ultimate objective obviously is a cure, meaning long -term, disease -free survival where every single neoplastic cell is eradicated.

But you know, if a cure is impossible, the strategy shifts to control.

Right.

We treat the cancer as a chronic disease to prevent it from enlarging or spreading, basically extending survival and maintaining quality of life.

And if the cancer is in advanced stages where control is unlikely, we move to palliation.

Where the drugs might not extend survival, but they alleviate symptoms to keep the patient comfortable.

And the timing of the administration matters just as much, right?

Oh, absolutely.

So giving chemotherapy prior to a surgical procedure to shrink the cancer, that's called neoadjuvant chemotherapy.

Okay.

So before surgery.

Right.

But if we do surgery or radiation first and then give chemotherapy to clean up any hidden microscopic spread,

that's adjuvant chemotherapy.

Adjuvant.

Got it.

And finally, maintenance chemotherapy is given in lower doses to help prolong a remission.

Okay.

So now to grasp what these drugs are actually fighting, the text dives into tumor dynamics.

And I have to say, the sheer scale of the math here is just staggering.

It really is.

The smallest tumor burden that is physically detectable, which is usually when clinical symptoms first appear, is a one gram mass.

That's about the size of a small grape.

And that single grape -sized tumor contains one billion cells.

A billion.

From one grape.

Yeah.

And to understand how those billion cells behave, we really have to look at the cell cycle.

Figure 35 .5 in the book illustrates this beautifully.

Imagine the life of a cell as a pie chart.

It starts in G0, which is a resting state where it is not dividing.

Just hanging out.

Exactly.

Then it moves into G1 to synthesize the enzymes needed for DNA production.

Next is the crucial S phase, where the DNA is actually replicated.

Following that is G2, where the cell synthesizes the components required to physically split apart.

And finally, the M phase, mitosis, where the cell actually divides.

But wait, if cancer is defined by rapid uncontrolled growth,

wouldn't a massive tumor be incredibly vulnerable?

I mean, it seems like it should be easy to wipe out with drugs that target rapid division.

You know, it's a great paradox.

You would totally assume a larger tumor is more vulnerable.

But as tumors grow, their growth rate actually decreases.

Yeah.

A large tumor mass simply doesn't have the vascularization like the blood supply to provide oxygen and nutrients to its center.

So because they are starved of nutrients, many of those cancer cells just stop dividing and retreat into that G0 resting phase.

Oh, wow.

And if they're resting, they're basically invisible to chemotherapeutic drugs that only target the active cell cycle.

Precisely.

A large tumor has a surprisingly low percentage of actively replicating cells.

You often have to debulk it first with surgery or radiation, or use cycle nonspecific drugs to shock the remaining dormant cells back into active proliferation.

So they wake up.

Right.

And only then can your cycle -specific drugs actually hit them.

So if a big chunk of the tumor is hiding, how do we ever mathematically destroy it?

And I think this brings us to the concept of the log -col phenomenon that the book talks about.

The destruction of cancer cells follows first -order kinetics.

Yeah.

And this is crucial.

This means a dose of a drug doesn't kill a set number of cells, it kills a constant fraction of cells.

Right.

If you're visualizing this, think of dividing a number by 10 over and over again.

You get a smaller and smaller number.

But mathematically, you never quite reach absolute zero.

Never zero.

Like, for example, say a patient has leukemia, which is usually diagnosed when there are about one billion leukemic cells.

If your treatment has a massive 99 .999 % kill rate, you are still left with 10 ,000 cancer cells.

Yeah, that's what we call a five -log kill.

The patient's tumor burden drops drastically.

They feel fine, they have no symptoms, and they are officially in remission.

But those 10 ,000 cells are still there.

Still there.

If this were a bacterial infection, your immune system would easily sweep up 10 ,000 remaining bacteria.

But tumor cells are masters at evading the immune system.

Meaning additional treatment is almost always required.

And to make it even harder,

surviving cells physically hide in pharmacologic sanctuaries.

Oh, the sanctuaries, yeah.

Like the blood -brain barrier naturally prevents certain chemotherapeutic agents from entering the central nervous system.

So you might have to administer drugs intrathecally, like injecting them directly into the spinal fluid to reach leukemic cells hiding there.

And this mathematical reality is exactly why combination chemotherapy is so vital.

You might have heard of protocols like RCHOP for lymphoma.

You combine drugs that have entirely different cellular targets and, crucially, non -overlapping toxicities.

Because you can't just multiply the same side effects.

Right.

You want to maximize the fraction of cells killed without overwhelming the patient's organs with the exact same toxicity.

But the tumor cells still fight back, right?

Through multidrug resistance.

The textbook details this fascinating kind of terrifying mechanism called the P -glycoprotein pump.

Figure 35 .6 maps this out.

It's a transmembrane protein with six loops forming a central channel right in the cell wall.

And what does it do?

The cancer cell literally uses cellular energy ATP to physically pump the chemotherapy drugs back out into the bloodstream.

Just spits them right back out.

Exactly.

And through cross -resistance, if a tumor cell amplifies this pump gene to survive one drug, it suddenly becomes resistant to a whole host of structurally unrelated chemotherapy drugs.

That is wild.

And while we are fighting this complex cellular war, the rest of the patient's body is taking heavy fire.

Because these drugs circulate systemically and attack dividing cells,

normal tissues just become collateral damage.

It's unavoidable with these traditional agents.

Right.

It makes total sense that hair follicles, bone marrow, and the gastrointestinal tract take a massive hit.

I mean, those cells naturally divide rapidly in a healthy person.

But the textbook maps out some highly specific, seemingly random organ toxicities using a visual tool called Chemoman.

Oh, Chemoman.

It's a classic.

Yeah.

Figure 35 .33.

You picture a little stick figure and it maps the initials of the drugs onto the organs they destroy.

It's a really brilliant way to memorize which drug targets which organ.

For example, cisplatin is notorious for attacking the ears and the kidneys, causing severe hearing loss, or ototoxicity and nephrotoxicity.

Or take the heart.

The text specifically links the drug doxorubicin to cardiotoxicity.

It generates free radicals that specifically damage the cardiac muscle.

And then you have the lungs, which are targeted by blue amycin and busulfan.

Both are strongly associated with pulmonary toxicity and pulmonary fibrosis.

And we can't forget the bladder.

Cyclephosphamide is uniquely known to cause hemorrhagic cystitis, which is this incredibly painful severe bleeding of the bladder wall.

And down at the extremities, like the hands and feet on the Chemoman figure, drugs like vincristine and the taxanes cause profound peripheral neuropathy -like intense numbness and tingling.

And there's a heavy sobering reality discussed in the text regarding long -term risks.

Because antineoplastic agents, especially the alkylating agents, are mutagens that literally damage DNA, they can actually cause treatment -induced tumors.

Yeah, that's a tough one to grapple with.

A patient could be cured of their initial cancer, only to develop acute leukemia ten or more years later as a direct result of the cure.

It is a profound trade -off.

But to really understand how we manage these risks, we need to look at how the drugs execute Starting with a group I know you like to call the Impostors.

Yes, the antimetabolites.

They are structurally related to normal compounds inside the cell, so they act as fake building blocks for DNA and RNA.

They sabotage the S -phase of the cell cycle, right when the cell is trying to replicate its genetic code.

Methotrexate is the absolute classic example here.

Folic acid is essential for a cell to replicate, while methotrexate is an antifollate.

It completely inhibits an enzyme called dihydrofolate reductase, or DHFR.

By blocking DHFR, methotrexate starves the cell of the folate components it desperately needs to make DNA.

If methotrexate starves every single cell in the body of folate, how does the patient survive the treatment?

You're shutting down DNA synthesis everywhere.

It's a really brilliant biochemical workaround.

Figure 35 .9 illustrates this perfectly.

It's called the leukovorin rescue.

Leukovorin is essentially phylinic acid.

It's a specialized form of folate that has already bypassed the specific enzymatic step that methotrexate blocks.

Oh, I see.

Yeah, so you hit the patient with high -dose methotrexate to aggressively attack the cancer, and then at a very specific time, you administer leukovorin.

The normal cells take up the leukovorin, replenish their folate pools, and are literally rescued from the toxicity.

While the tumor cells still die.

Exactly.

It's pharmacology at its most precise.

The text also details other anti -metabolites, like 6 -mercaptopurin, a purine analog used frequently in acute lymphoblastic leukemia.

Interestingly, it's also used to manage Crohn's disease, but it carries a dose -limiting hepatotoxicity.

Meaning, it severely damages the liver.

Right, requiring constant clinical monitoring.

Okay, so let's say a cancer cell somehow survives the S phase.

It manages to make its DNA and enters the M phase to physically divide.

We have another trap waiting, right?

The microtubule inhibitors.

We do.

Figure 35 .23 shows this process.

For a cell to divide in mitosis, it has to pull its duplicated chromosomes apart.

It achieves this by building a temporary scaffold out of tubulin molecules, which stack together to form what's called a mitotic spindle.

This is where drugs like the taxanes, specifically paclitaxel, step in.

Paclitaxel binds to that tubulin scaffold and makes it unusually stable.

Right, overly stable.

Yeah, the tubulin molecules stack up to form the spindle, but they fail to depolymerize.

They can't break back down.

So the entire cell gets completely frozen in metaphase.

It is physically stuck, attempting to divide, and eventually it just dies.

Clinically, though, paclitaxel triggers severe hypersensitivity reactions.

To prevent the patient from experiencing dyspnea, hives, or dangerous hypotension, they must be heavily premedicated with dexamethasone and dufenhydramine before the 5 -e has even The other major players here are the vinka alkaloids vincristine and vinblastine.

Connecting this back to our chemoman toxicities, vincristine causes the peripheral neuropathy, while vinblastine causes severe bone marrow suppression.

And we have to highlight a massive clinical warning from the techs for these two.

They must never be administered intrathecally.

Injecting a vinka alkaloid into the spinal fluid is uniformly fatal, and hospitals require incredibly strict protocols to prevent that specific error.

Now, everything we've talked about so far relies on disrupting the physical mechanics of cell division.

But some tumors operate on a completely different fuel source, the body's natural hormones.

Breast and prostate cancers are the main culprits here.

If a breast tumor is hormone dependent, it is actively feeding on estrogen.

We can use a drug like tamoxifen, which is a selective estrogen receptor modulator, or a CIRM.

Okay, so it binds to the estrogen receptors in the breast tissue, basically blocking the actual estrogen from attaching.

Yes.

But this is where the pharmacology gets highly complex.

Tamoxifen acts as an antagonist, a blocker in the breast.

But in the endometrium of the uterus, and in the bone, it acts as an agonist.

It actually mimics estrogen.

Hold on.

You are giving a patient a drug to starve an estrogen -feeding cancer in their breast, but that same drug is actively stimulating the estrogen receptors in their uterus.

Doesn't that just trade one cancer for the risk of another?

Unfortunately, yes, it does.

Because it stimulates the endometrial tissue, tamoxifen carries a distinct, documented risk of causing endometrial cancer.

It also increases the risk of thromboembolism, or blood clots.

To circumvent that risk, the text brings up aromatase inhibitors, like anastrazole and letrazole.

Great.

Instead of competing at the receptor level, aromatase inhibitors stop the body from producing extra adrenal estrogen in the first place.

For postmenopausal women, this peripheral estrogen is their main supply.

Because their ovaries have stopped.

So these drugs cause an almost total suppression of estrogen synthesis, and crucially, they do not predispose patients to endometrial cancer.

That makes them a preferred first -lying choice.

And when dealing with prostate cancer, we use GnRH analogs, like luprolide.

And the mechanism here is completely counterintuitive.

It really is.

GnRH is a hormone that normally stimulates the pituitary gland to release signals that eventually tell the testes to manufacture testosterone.

If you administer a continuous synthetic analog of GnRH, like luprolide, it constantly occupies that receptor on the pituitary.

You are essentially flooding the engine.

Exactly.

Because the receptor is constantly occupied, it becomes overstimulated, eventually desensitizes, and just shuts down entirely.

So it just gives up.

Pretty much.

Clinically, you see an initial tumor flare as testosterone briefly spikes, but then the whole endocrine feedback loop crashes.

It drops the patient's testosterone to castration levels without requiring physical surgery.

It's an incredibly clever manipulation of the body's own feedback loops.

But if we need to abandon cleverness and just bypass the cell cycle entirely, we bring in the heavy metals,

the platinum coordination complexes.

Oh, yes.

These are the true sledgehammers of oncology.

Cisplatin, carboplatin, oxyloplatin, they directly assault the DNA structure.

And their mechanism is driven by the chemical environment.

How so?

Well, in the blood plasma, where chloride levels are high, cisplatin stays chemically neutral.

But the moment it crosses into a cell where the chloride concentration is very low, it loses a chloride ion.

And that shift makes it highly reactive.

It binds directly to the guanine bases in the DNA and physically cross -links the DNA strands together.

Imagine, like, wielding a zipper shut.

That's a great analogy.

Thanks.

The DNA can't unzip, it can't replicate, and the cell is destroyed.

But linking back to chemoman, this sledgehammer approach is highly toxic.

Cisplatin causes severe nausea and vomiting that can last for days, requiring heavy anti -medic drugs.

Right.

And because its dose -limiting toxicity is severe nephrotoxicity, clinical teams have to aggressively pre - and post -hydrate the patient,

flooding their system with IV fluids to protect the kidneys from being destroyed as the drug is excreted.

The text also highlights oxaloplatin in this class, which causes a truly bizarre adverse effect, a cold -induced peripheral neuropathy.

Yeah, that one is unique.

If a patient touches something cold, or even drinks a cold beverage, it triggers severe nerve pain and numbness in their extremities.

It usually resolves within 72 hours, but it is deeply uncomfortable.

Now, if we can't weld the DNA shut with platinum, another strategy is to target the enzymes that uncoil it.

To replicate, DNA has to untwist.

Think of DNA like one of those old coiled telephone cords.

When you try to pull the strands apart to copy them, the cord gets incredibly super coiled and tight ahead of the split.

Figures 35 .29 and 35 .3 show this.

To relieve that tension, the cell uses two poissamerase enzymes.

They act like little molecular scissors.

They snip the DNA to let it unwind a bit, and then instantly seal it back up so the copying can continue.

And drugs known as the Camptothasins, like urinotikin and topotikin, block the poissamerase thesert.

Right, they prevent the enzyme from working, causing fatal DNA damage.

But urinotikin is famous for a brutal clinical side effect, acute and delayed life -threatening diarrhea.

That sounds awful.

It is.

It is so severe it often requires treatment with atropine right during the 5V infusion, or massive doses of loperamide for days afterward.

Then there is etoposide, which targets the poissamerase too.

It actually binds to the enzyme -DNA complex and prevents the enzyme from sealing the snip it just made.

You end up with irreversible double -strand breaks.

The DNA is literally shredded.

Wow.

Well, this brings us to the frontier of the chapter.

We are finally moving away from the systemic blunt -force trauma of the chemoman drugs toward targeted cellular machinery.

This is the era of tyrosine kinase inhibitors, or TKIs.

Kerosene tineses are enzymes that act like on -switches for cell growth and division.

In many cancers, these kinases are mutated and physically stuck in the on position.

Just constantly telling the cell to divide.

TKIs are oral agents, daily pills, that specifically inhibit these exact mutated enzymes.

It's a massive shift from IV drips of systemic toxins to targeting a specific genetic mutation.

We also use immunomodulators like thalidomide and linalidomide, primarily for multiple myeloma.

They have anti -angiogenic properties, meaning they basically choke off the tumor's ability to grow new blood vessels.

But the text provides a pretty dark historical context here.

Thalidomide was originally prescribed to pregnant women in the mid -20th century to prevent morning sickness, and it resulted in devastating limb deformities in newborns.

Because of that history and their mechanism, these drugs carry incredibly strict contraindications regarding pregnancy today.

Finally, the text touches on monoclonal antibodies.

While they are highly targeted, they are not without risks, especially when combined with the older drugs we've discussed.

For sure.

When targeted antibodies, like Trastuzumab, are paired with traditional anthracyclines like doxorubicin, which is the one that damages the heart via free radicals, the patient's risk of heart failure skyrockets.

So how do you manage that?

Clinicians sometimes have to administer an iron chelator called dexrazoxane alongside the chemo just to try and protect the cardiac tissue.

You know, looking back, the entire history of pharmacology in Chapter 35 is just this delicate mathematical tightrope walk between destroying a tumor and rescuing the host.

As we move from the blunt force of the drugs that make up Chemoman to the exact genetic targeting of the TKIs, we're kind of redefining what it physically means to cure a human body.

It really is an incredible evolution of science, but it requires a deep understanding that every mechanism we manipulate carries a profound consequence.

And with that, you have made it through one of the most intense,

complex chapters in the book.

A huge warm congratulations and thank you specifically from the Last Minute Lecture team.

You successfully navigated the cellular physiology, the mechanisms, the math, and the medicine.

You've got an incredible foundation now.

I think so too.

So next time you're trying to pull a single weed out of a pristine lawn without ruining the grass, just think about Leucovore and Rescue and P -glycoprotein pumps.

Until next time, keep diving deep.